Loading...
Roivant Sciences Community
NasdaqGS:ROIV Community- 1 Narratives written by author
- 0 Comments on narratives written by author
- 15 Fair Values set on narratives written by author
Community Investing Ideas
ROIV: Positive Phase 3 Results And Legal Uncertainty Will Shape Medium-Term Outlook
Key Takeaways Successful clinical trials and strategic deals may improve revenue and net margins by focusing on high-value areas. Potential in-licensing and late-stage pipeline approvals could significantly enhance earnings and portfolio sales impact.Read more
1users have liked this narrative
0users have commented on this narrative
6users have followed this narrative
AN
US$24.55
14.6% undervalued intrinsic discount
AnalystConsensusTarget Fair Value
Revenue
326.15% p.a.
Profit Margin
4.29%
Future PE
290.43x
Price in 2028
US$30.44
